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Abstract 
Parkinson’s disease is a motor system disorder that is caused primarily by the loss of 
dopamine-producing brain cells. The most affected brain structure is the pars compacta of 
the substantia nigra. This area of the brain is essential to the control of voluntary 
movement, and so its impairment leads to symptoms such as tremors, rigidity, and 
impaired balance. The neuronal protein alpha-synuclein has been shown to be heavily 
involved in the pathogenesis of the disease at the cellular level. The currently available 
treatments for PD mainly target dopamine regulation, and there been no cure developed 
for the disease at present. New treatments must be explored by an evaluation and 
synthesis of the current research and should be adjusted for each patient individually. 
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Parkinson’s Disease: Molecular Mechanisms and Treatments 
 
The biological mechanisms and treatment pathways for Parkinson’s disease (PD) 
are slowly being uncovered. The molecular basis of the disease and its various causes are 
the fundamental starting point of this process. In order to understand how the symptoms 
of Parkinson’s present and how they can be targeted, it is important to determine how the 
molecular pathology affects the PD patient on a macroscopic level. The currently 
available treatments for PD are continually being improved and expanded upon since 
there has been no cure developed for the disease at present. Possible new avenues for 
treatment must be explored by an evaluation and synthesis of the current research and 
therapy options available. 
Introduction and Justification of Research Approach 
Parkinson’s disease is a disorder of the motor system. It is caused primarily by the 
loss of dopamine-producing brain cells.  There are four main symptoms of PD: tremors, 
rigidity, bradykinesia, and impaired balance and coordination. All of these symptoms 
have a molecular- and cellular-level basis, much of which has yet to be completely 
revealed. The most notable brain structure damaged in Parkinson’s disease is the pars 
compacta, a part of the substantia nigra. The neurons in this area of the brain are part of a 
pathway for the control of voluntary movement and they use the neurotransmitter 
dopamine. When dopamine is not present at normal levels, as in the case of PD, this 
causes an individual’s ability to coordinate movement to be significantly impeded. 
Because of the diversity and variability inherent in the clinical manifestation of 
Parkinson’s disease, the diagnoses are often broadened into a spectrum of disorders 
known as parkinsonisms. Furthermore, the diagnostic criteria of the disease have changed 
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over time. These criteria have been developed based on both the symptoms that are 
observed in Parkinson’s disease patients and their underlying molecular causes. 
Confirmation of the presence of the disease is sometimes not apparent until the 
patient has died and a postmortem examination has been made. Although strict criteria 
have been developed and accepted for the diagnosis of Parkinson’s disease, there still 
exist certain gray areas in diagnostics. Certain specifics of the disease currently qualify 
as parkinsonisms, but these aspects deserve attention due to their relevancy and 
correlation to the purported Parkinson’s disease. 
 Parkinson’s disease has a variety of genetic sources. However, several epigenetic 
causal factors have been identified as well. There is evidence that one of these factors is 
an increase in the formation of reactive oxygen species. These reactive species can 
originate both inside and outside the mitochondria (Zhou, Huang, & Przedborski, 2008). 
Another causal factor may be toxins in the environment. For example, a 
contaminant found in some illegal drugs in the 1980s, methyl-4-phenyl-1,2,3,6-
tetrahydropyridine (MPTP), was found to lead to the development of parkinsonism in 
drug users. MPTP is soluble in lipids and so it is able to cross the blood-brain barrier. The 
toxin is then modified inside the brain and is recognized by the dopamine transporter. 
This is extremely detrimental to the neurons because the molecule binds to NADH 
dehydrogenase and essentially terminates the electron transport chain. Starved for ATP, 
these cells shortly die. 
Besides the environmental causes of Parkinson’s and parkinsonisms, there are 
several common genetic mutations that can occur that lead to the disease. Possible sites 
for a mutation include PARK1, the gene that codes for α-synuclein, and PARK2 through 
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PARK12. There is strong evidence that α-synuclein plays a principal role in the 
development of Parkinson’s disease. However, due to the delicate complexity of PD, 
there are likely to be many different important proteins involved in the process and these 
principal proteins may differ in the extent of their role from patient to patient. Each of the 
gene products transcribed from the PARK family of genetic mutations has a distinctly 
different effect on the operation of the neuron in which it is produced. 
In order to study how each of these proteins leads to the overall expression of 
common Parkinson’s disease symptoms in a patient, their normal function must be 
elucidated. Knowledge about the normal functioning of these proteins can be just as 
important as an understanding of their pathogenic behavior. As research has shown, much 
of the pathology of Parkinson’s disease must be explained not only by the loss of 
function of a protein or brain region, but also by a gain of function that is detrimental to 
the normal working of the cell. 
The immediate goal of the current research being conducted on Parkinson’s 
disease is to provide a description of how each specific molecular pathway works to 
affect the Parkinson’s disease patient on a macroscopic level. The most prominent 
questions that today’s researchers seek to answer are problems such as these: how does 
the aggregation of the protein α-synuclein impair the PD patient’s cognitive and motor 
skills? What specific symptoms are made manifest by this molecular abnormality? 
Parallels will be drawn between each of the causal factors of the disease and their 
respective expressions in the patient’s physiology. 
 The currently available treatments for Parkinson’s disease are continually being 
accumulated and modified as new research reveals target areas for development. The 
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disease was originally thought to have been acquired de novo due to environmental 
factors or toxins. However, within the last ten years or so, increasing evidence for the 
genetic basis of the disease has surfaced. Understanding these mutations and inherited 
traits better will open countless avenues for treatment, from drug development to gene 
therapy.  
Each of the molecular mechanisms of the disease presents a unique opportunity 
for management of the symptoms it produces. The experiments described in this review 
investigate how and where each pathogenic molecular pathway may be intercepted, 
perhaps with a new drug, that would restore the natural biological process or at least 
mitigate the effects of the disease. Noting the diversity of Parkinson’s disease cases, it is 
probable that the conclusion of this problem will be a multifaceted one. It is likely that 
the various mechanisms of the disease, while there will be many parallels, will also differ 
substantially. Because of this, a multiplicity of treatments will be proposed to fit each 
distinct case in a uniquely appropriate way. 
Alpha-synuclein and the Pathology of Parkinson’s Disease 
Current Parkinson’s Disease Research Techniques 
The biological and chemical mechanisms regarding abnormal protein aggregation in the 
brain of Parkinson’s disease (PD) patients is forefront in the developments of Parkinson’s 
disease research. The molecular basis of the disease and its various causes have been 
investigated and analyzed, according to the results of previous experiments. Extensive 
Parkinson’s disease research is also conducted at hundreds of other labs and institutions 
across the world, including the National Institutes of Health (NIH). This research seeks to 
explain how these mechanisms correlate with the most common treatment pathway of the 
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disease. Last, the effectiveness of L-DOPA as a treatment for Parkinson’s disease 
treatment will be analyzed. 
Molecular Techniques Reveal the Cellular and Molecular Mechanisms 
Parkinson’s disease has a variety of genetic and epigenetic sources. These sources have 
been discovered and analyzed by a plethora of methods, including NMR, 
spectrophotometry, genetic techniques, proteomics, neuroproteomics, analysis of enzyme 
kinetics, and pharmacokinetics. Specific results from selected techniques will be 
described throughout the discussion in order to analyze further the mechanism of protein 
aggregation in Parkinson’s disease. 
One of the most important sources for Parkinson’s disease pathology appears to 
be the abnormal aggregation of a protein called α-synuclein in the brain. Alpha-synuclein 
has only primary structure, and there is generally no secondary or tertiary structure 
determined by its amino acid sequence. Many proteins that remain in an unfolded state 
serve as chaperones in the cell and can aid in the folding of new proteins  (Irvine, El-
Agnaf, Shankar, & Walsh, 2008). However, NMR spectroscopy has revealed that when 
α-synuclein is bound to a lipid or micelle surface, the protein will adapt a secondary 
structure: a right-handed alpha helix interrupted by a single break (Bussell & Eliezer, 
2003). 
Parkinson’s disease is confirmed in large part by the presence of Lewy bodies 
(LB) in the substantia nigra, which are found in the brains of autopsied PD patients. 
Lewy bodies occur in several other neurodegenerative diseases as well (Shults, 2006). 
Alpha-synuclein has been found to be the primary component of LB. This protein is 
found in presynaptic nerve terminals and associates with the membranes of vesicles in the 
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synapse  (Irvine et al., 2008). This association is most likely due to the formation of the 
right-handed alpha helix structure it forms when associated with lipids. 
There are several stages involved in the kinetics of α-synuclein aggregation, and 
some of these stages can be altered by nutraceuticals (Mazzio, Close & Soliman, 2011). 
The first step is that an α-synuclein monomer must be modified; the second is the 
interaction of modified monomers to form small aggregates; the third is the elongation of 
these aggregates into fibrils, which are subsequently deposited in neurons and Lewy 
bodies (Mazzio, Close & Soliman, 2011). 
Spectrophotometry is widely used in the determination of enzyme kinetics related 
to Parkinson’s disease, especially in relation to the enzyme Tyrosinase. Tyrosinase 
catalyzes several different reactions in the body, including the conversion of L-Tyrosine 
into L-DOPA (Chang, 2009). L-DOPA is an intermediate in the pathway to dopamine, 
and so this enzyme is of great interest to PD research. 
In the kinetic analysis of Tyrosinase, varying amounts of enzyme, substrate, 
inhibitor, or whichever aspect of the reaction is to be studied, are added to reaction 
mixtures (Duckworth & Coleman, 1970). These mixtures are immediately placed in a 
spectrophotometer and the absorbencies are read at consistent time intervals. The speed 
of the reaction can then be determined from these recorded values by plotting a graph. 
A Michaelis-Menten plot is used for an enzyme-catalyzed reaction in order to 
determine Vmax, the maximum velocity of the reaction, and KM, the Michaelis constant. In 
addition, a Lineweaver-Burk plot can be used to analyze the inhibition of the enzyme 
(Duckworth & Coleman, 1970). This is also useful in PD research because Tyrosinase 
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has a large number of biochemical inhibitors and multiple catalytic activities (Chang, 
2009). 
Two Possible Conclusions from the Available Data. 
The primary structure of the α-synuclein protein is tripartite. That is, it consists of three 
distinct but connected regions: the α-helical N-terminal region, the central region, and the 
C-terminal region. The α-helical N-terminal region is used to bind hydrophobic lipid 
membranes (Irvine et al., 2008). Without this region, α-synuclein would not be able to 
bind to vesicles in the synaptic cleft. Thus, it could be inferred that a mutation in this 
sequence could cause a loss of function of the α-synuclein gene product. 
 However, α-synuclein may still be able to aggregate easily if the central region 
were to remain intact. The central portion of the α-synuclein polypeptide is composed of 
hydrophobic amino acids that are prone to association with other similarly hydrophobic 
molecules. On the other hand, the C-terminal region of α-synuclein is made up of many 
hydrophilic amino acids, largely aspartate and glutamate, including a significant number 
of prolines. This portion of the α-synuclein polypeptide will naturally tend to have 
contact with the surrounding cytosol or other charged molecules near it. 
Alpha-synuclein aggregates, a primary defining feature of Parkinson’s disease, 
are most often attributed to the action of the hydrophobic central region  (Irvine et al., 
2008). Because hydrophobic molecules have no dipole to attract the dipole of water, 
water is far more attracted to its own molecules, leading to aggregation of these 
predominately Van der Waals molecules. These large aggregates of α-synuclein then 
coalesce further into more ordered aggregates known as amyloid fibrils, thereby 
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decreasing the entropy of these molecules (Bussell & Eliezer, 2003). Fibrils found 
purified from Lewy bodies resemble closely the structure of these amyloid fibrils. 
As previously mentioned, Lewy bodies containing α-synuclein aggregates and 
amyloid fibrils are found in autopsies of the brains of Parkinson’s disease patients. It is 
interesting to note that dopamine and other similar catecholamines have been found to 
stabilize the protofibril stage of α-synuclein aggregation by their specific interactions  
(Irvine et al., 2008). Lewy bodies are found predominately in the substantia nigra, and so 
a question of cause and effect arises. The substantia nigra is so named because of the dark 
pigmented neurons found in that area; this pigment is a by-product of dopamine 
synthesis. Therefore, there are two possible conclusions. 
Inferences to Guide the Development of Therapies 
The first possible conclusion is that the neurons of the substantia nigra are more 
susceptible to α-synuclein aggregation due to their high level of dopamine production  
(Irvine, El-Agnaf, Shankar, & Walsh, 2008). The second conclusion is that the lack of 
dopamine production by the cells in the substantia nigra leads more directly to the motor 
dysfunction symptoms of Parkinson’s disease. Another piece of information that may 
serve to clear up this issue is related to pharmacokinetics. The most commonly prescribed 
and most widely effective drug for PD is L-DOPA, also commonly known as levodopa 
(Stocchi, 2006). 
 L-DOPA, unlike the neurotransmitter dopamine, can cross the blood-brain barrier 
(Stocchi, 2006). Once in the brain, it is hydroxylated and converted by the enzyme 
tyrosinase into dopamine by a series of steps (Chang, 2009). This drug has been shown to 
be effective until about 3-5 years of treatment have gone by (Pienaar, Daniels, & Gotz, 
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2008). After this initial period, L-DOPA begins “wearing off,” and the symptoms of PD 
return in force (Pienaar, Daniels, & Gotz, 2008). 
These conclusions, among others, are debated in the scientific community—
especially as to which of the mechanisms researched have the most significant impact on 
the genesis, course, and termination of the disease. These controversies are unavoidable 
however, due to the multi-faceted nature of Parkinson’s disease and the many factors and 
molecules involved in each process. The most probable explanation will be an integrated 
synthesis of each of the mechanisms proposed, and this will vary from individual to 
individual. 
Outlook and Proposed Mechanism 
In light of these factors, one possible inference is that certain cases of Parkinson’s disease 
begin with an elevation in the level of dopamine being produced in the pars compacta of 
the substantia nigra. This increased level of dopamine may lead to increased α-synuclein 
aggregation, seeing that dopamine stabilizes the protein’s protofibril. This aggregation, 
toxic to the cells of the pars compacta, may over time lead to lack of dopamine 
production—a decrease in the levels of dopamine due to the death of pigmented neurons. 
This in turn would lead to the motor dysfunction symptoms characteristic of PD.  
When L-DOPA is prescribed, the artificially increased levels of dopamine in the 
brain may mitigate these symptoms for a particular duration of time. However, the 
increased dopamine (if not properly regulated) could easily lead to a further increase in 
the aggregation of α-synuclein. As the drug continues to affect the PD patient’s body and 
brain, extensive aggregation may eventually occur, possibly after about 3-5 years. By this 
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time, the toxic aggregates and amyloid fibrils may have almost completely destroyed the 
pars compacta. 
If this occurs, there would no longer be much free α-synuclein nor cells in the 
pars compacta capable of regulating the level of dopamine. In this case, L-DOPA would 
no longer continue to be effective, as seen in the majority of clinical cases. Whether this 
hypothesis is correct or not remains to be determined. However, it is likely that this 
mechanism, if found to occur, is only a part of the course of this disease and only in 
certain cases. 
Extensive research remains to be done on the problem of the mechanisms of 
Parkinson’s disease, especially when it comes to the intricacies of protein aggregation. 
This work will most likely take years and even then a definite conclusion will probably 
not be found. The mechanism of PD may never be resolved completely due to the high 
degree of diversity and variability inherent in the disease. 
It is clear that new avenues for research need to be explored, specifically in the 
areas of interaction between the various mechanisms. The solution is most likely to be a 
balance and conglomeration of several different methods because Parkinson’s is very 
much a multifaceted disease. The more research that is done, especially with the added 
understanding that there can never be one perfect fix, may not eradicate the problems of 
the disease but may one day make it a highly survivable and recoverable disease. 
Alpha-synuclein and Dopamine Levels in the Parkinson’s Disease Brain 
One of the hallmarks of Parkinson’s disease (PD) is the abnormal aggregation of a 
protein called α-synuclein in the brain (Irvine et al., 2008). Parkinson’s disease is 
confirmed in large part by the presence of Lewy bodies (LB) in the substantia nigra, 
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which are found in the brains of autopsied PD patients (Shults, 2006). Alpha-synuclein 
has been found to be the primary component of LB (Irvine et al., 2008). This protein is 
found in presynaptic nerve terminals and associates with the membranes of vesicles in the 
synapse (Irvine et al., 2008). 
 Considering the primary structure of α-synuclein, it is clear that there are three 
distinct regions. The N-terminal region is composed of a repetitive sequence of amino 
acids, an “α-helical lipid-binding motif of apolipoproteins” (Irvine et al., 2008, pg. 458). 
This section is essential for the binding of α-synuclein to vesicles in the synaptic cleft. 
The central stretch of the sequence is made up of many very hydrophobic amino acids 
(Irvine et al., 2008). In contrast, the C-terminus is composed of predominately 
hydrophilic residues. 
Alpha-synuclein aggregates may be caused chiefly by problems arising from this 
exceedingly hydrophobic central region. These large aggregates of α-synuclein then 
coalesce further into more ordered aggregated known as amyloid fibrils. The two articles 
discussed in this paper investigate the effects of increased expression of α-synuclein on 
neurons, a common cause of the PD pathology.  
Synthesis of Two Related Experiments Examining the Effects of Alpha-synuclein 
Levels on the Cell 
Review of Experiment 1: Effect of Alpha-synuclein Levels on Synaptic Vesicle 
Reclustering. The first article, “Increased Expression of Alpha-Synuclein Reduces 
Neurotransmitter Release by Inhibiting Synaptic Vesicle Reclustering After 
Endocytosis,” found that over-expression of α-synuclein significantly inhibits the release 
of neurotransmitters (Nemani et al., 2010). To elucidate the role of α-synuclein at the 
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synapse, a special type of imaging technique was used. A fusion of vesicular glutamate 
transporter 1 (VGLUT1) to the modified GFP ecliptic pHluorin (VGLUT1-pHluorin) 
served to monitor the exo- and endocytosis of synaptic vesicles via the pH changes and 
accompanying change in fluorescence of the pHluorin that occur during the release of a 
vesicle. VGLUT1-pHluorin was co-transfected with either the wild type human α-
synuclein or the control, an empty vector, into embryonic hippocampal neurons for in 
vitro analysis (Nemani et al., 2010).  
 This method revealed that the over-expression of α-synuclein inhibits the 
exocytosis of synaptic vesicles (Nemani et al., 2010). Electrophysiology experiments in 
transgenic mice over-expressing α-synuclein also exhibited inhibition of synaptic 
transmission. These mice showed significantly less baseline transmission than wild type, 
with results similar to those obtained in culture. The inhibition effect of α-synuclein was 
also seen in the rat ventral midbrain, which contains approximately 90% dopamine 
neurons (Nemani et al., 2010). 
 Further imaging using VGLUT1-pHluorin and related imaging techniques 
revealed that the over-expression of α-synuclein results in a reduction of the readily 
releasable and recycling synaptic vesicle pools. It was also found that this over-
expression affects the reclustering of synaptic vesicles after endocytosis. This evidence 
obtained by VGLUT1-pHluorin analysis was confirmed by a GFP-VGLUT1 control 
(Nemani et al., 2010). 
 The imaging of GFP-VGLUT1 provided direct evidence for the problem with 
synaptic vesicle reclustering because it showed the entire time course of the reclustering 
of synaptic vesicles after endocytosis. This confirmation supports the conclusion of the 
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article, which was that the increased levels of α-synuclein seen in both sporadic and 
familial PD reduce the amount of neurotransmitter released by inhibiting the recycling of 
synaptic vesicles after endocytosis. 
Review of Experiment 2: Effect of Alpha-synuclein Levels on Dopamine Toxicity. 
The second study, “α-Synuclein Overexpression Increases Dopamine Toxicity in BE(2)-
M17 Cells” by Bisaglia et al. (2010), explored the interplay between α-synuclein and 
dopamine. This experiment specifically investigated the possible role of oxidative stress 
in Parkinson’s disease by looking at the redox reactions in nigral dopaminergic neurons. 
Dopaminergic human neuroblastoma BE(2)-M17 cells were transfected with WT or 
A30P mutant α-synuclein (Bisaglia et al., 2010). Then, cellular toxicity was measured. 
 Two methods were used to measure cellular toxicity: lactate dehydrogenase 
(LDH) activity-based cytotoxicity assay and fluorescence-activated cell sorter (FACS) 
analysis (Bisaglia et al., 2010). For the lactate dehydrogenase assay, cells were plated 
into wells with growth medium and supplemented with dopamine (DA). Catalase was 
used as a control to remove any hydrogen peroxide produced by extracellular 
catecholamine oxidation. This control was necessary in order to study only the 
intracellular effects of DA oxidation. Once the lactate dehydrogenase assay was 
performed, the percentage of cell death was calculated by the ratio of the activity of LDH 
in the supernatant to the total LDH activity (Bisaglia et al., 2010). 
 The expression levels of both types of α-synuclein were about 6 to 8 times higher 
than the control cells, indicating a level most likely slightly higher than that seen in most 
PD cases (Bisaglia et al., 2010). The results showed that DA induced cell damage in all 
cell lines, and that cells overexpressing either the mutant or WT α-synuclein were more 
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susceptible to the dopamine-induced toxicity (Bisaglia et al., 2010). Fluorescence-
activated cell sorter analysis was performed to confirm that the overexpression of α-
synuclein increased cell vulnerability to DA by sorting the viable cells from the necrotic 
and apoptotic cells. These results confirmed those of the lactate dehydrogenase assay 
(Bisaglia et al., 2010). 
 Previous studies have shown that oxidized DA can covalently modify α-
synuclein, stabilizing its protofibril form. The main results of this study were that over-
expression of both WT and mutant α-synuclein produce toxic effects on the cell and that 
α-synuclein and DA are more toxic together than the sum of their individual toxicities 
(shown by graphed FACS results). It is believed that this synergistic effect is due to the 
modification of α-synuclein by oxidized DA in the cytosol (Bisaglia et al., 2010). 
 There are many issues left unclear at the conclusion of this experiment. For one, 
the title of this article claims that “α-synuclein overexpression increases dopamine 
toxicity.” However, the conclusion claims that “DA exposure increases the toxicity of the 
PD-related protein α-synuclein.” Does α-synuclein increase dopamine toxicity or does 
DA increase α-synuclein toxicity? The conclusion avoids this question by calling this a 
“synergistic toxic effect” (Bisaglia et al., 2010, pg. 5). 
 It is clear from the results of this and other experiments that DA and α-synuclein 
can together produce a toxic effect. Although this is true, some of the statements that 
were made in this article regarding cause and effect most likely need further 
investigation. In other words, the direct or indirect pathway by which α-synuclein 
increases the toxicity of DA (or vice versa) has not been made clear by this experiment, 
and still remains to be determined. 
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Contributing factors have a synergistic effect on cytotoxicity. 
 Collectively, the two articles discussed in this paper show the detrimental effects 
of the over-expression of α-synuclein on the brain. These findings are relevant to the 
current research in Parkinson’s disease because α-synuclein is commonly over-expressed 
due to genetic defects causing multiple gene copies, as previously mentioned. In the first 
article, it was found that an increased level of α-synuclein in the cell reduces the amount 
of neurotransmitter released by inhibiting the recycling of synaptic vesicles after 
endocytosis. In the second article, the synergistic toxicity of α-synuclein and dopamine 
was explored and quantified. 
 These articles may together contribute to the elucidation of the PD pathology in 
several ways. The most important of these relates to the level of intracellular dopamine in 
the substantia nigra neurons. Since we know from the first experiment that the vesicle 
recycling after endocytosis is inhibited in the presence of over-expressed levels of α-
synuclein, it may be inferred that the levels of dopamine in these cells is increased. Since 
the cells of the substantia nigra normally release the neurotransmitter dopamine into the 
synaptic cleft of their target cells, the impairment of these cells in releasing DA might 
cause elevated levels inside of the neuron. 
 There may be some mechanism by which the cell compensates for this abnormal 
increase in dopamine caused by the decreased synaptic vesicle recycling. However, if 
not, this DA increase would certainly be consistent with the results obtained in the second 
article. In that experiment, each cell line was treated with increasing concentrations of 
DA, and then the extent of cellular toxicity was determined. As the concentration of DA 
used was increased, the level of cell death also increased accordingly. As expected, the 
PARKINSON’S DISEASE                         19 
cells expressing both WT and mutant α-synuclein were more susceptible to cell death 
with this induced dopamine increase. 
 The results of both of these articles suggest a mechanism by which the over-
expression of α-synuclein in the Parkinson’s disease brain could lead to neuronal death. 
There are several contributing factors involved in this mechanism, most of which have a 
synergistic effect on cytotoxicity. First of all, the hydrophobic central region of the α-
synuclein protein contributes to the propensity of these monomers to aggregate. Further, 
oxidized dopamine is known to stabilize the protofibril stage of this protein’s fibrillation. 
Thus, an increase in the expression of α-synuclein adds to this problem by increasing the 
propensity of these monomers to aggregate and augments their cytotoxicity. 
 With more α-synuclein aggregates, less dopamine is released from vesicles into 
the synaptic cleft. This may cause a build-up of dopamine in the cell, surpassing normal 
levels even for the dopaminergic neurons. More dopamine causes more stabilization of 
the α-synuclein protofibril, which in turn leads to further aggregation. This cyclic effect, 
if shown to be valid, would explain in part why the L-DOPA treatment is ultimately 
ineffective in PD patients.  
 In order to validate this hypothesis, the levels of intracellular dopamine would 
have to be monitored in dopaminergic cells like those of the substantia nigra. Similar 
experimental setup, like that of the second experiment, would be useful. However, one 
change would be that the cells should be tested with some type of fluorescently detectable 
dopamine. If the level of dopamine inside the cells could be visualized by a using a 
fluorescent tag, the amounts could be quantified and compared between samples. 
 The experimental setup of the second experiment would be useful if the same 
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variable and controls were used. The WT and A30P mutant α-synuclein variants along 
with the same increasing levels of dopamine could be employed. After each cell line was 
treated with the specific amount of dopamine being used in that trial, the cells could be 
visualized using fluorescence microscopy. Then, stereology could be used to quantify the 
amount of fluorescence seen in each sample. 
Impact of synthesis and prospects for further experimentation. Both of these 
experiments have broadened knowledge about the interconnected pathways responsible 
in PD pathology. The suggested experiment should help to clarify the question of whether 
α-synuclein causes increased intracellular levels of dopamine. It will also assist in the 
understanding of this disease by authenticating the hypothesis that high levels of 
dopamine inside these cells contributes to cell death, as this could be measured using the 
same techniques as in the second experiment discussed. Overall, together these 
experiments will further aid in the dissection of cellular-level PD pathology as it relates 
to the over-expression of the α-synuclein gene. 
The Development of Potential Therapies for Parkinson’s Disease 
Approaches to Parkinson’s disease therapy 
 There are many approaches to Parkinson’s disease therapies, including both 
neuroprotective and neurorestorative therapies. Neuroprotective therapies mainly seek to 
prevent the spread of pathogenesis to new neurons and brain regions. On the other hand, 
the goal of neurorestorative therapies is to return diseased neurons to their healthy 
processes. Some neurorestorative therapies also seek to replace the cells that have already 
died. 
 At this time, when dopamine prescription is in widespread use for the treatment of 
Parkinson’s Disease, the symptoms of the disease that are unrelated to neurodegeneration 
PARKINSON’S DISEASE                         21 
in the midbrain have become most prominent. Symptoms such as depression, dementia, 
and cognitive decline have the strongest effects on patient mortality. Furthermore, it is 
these symptoms that arguably have the most poignant effect on a patient’s quality of life 
(Sen & West, 2009). 
 However, it is important to note that these different categories of symptoms are 
intricately and inextricably related to one another. Although different approaches will be 
needed to target each system, there is much evidence for the effectiveness of therapies 
that try to attack both categories at once. For instance, recent research has shown that 
both Parkinson’s Disease and depression may be mediated by the same mechanism. They 
have both been linked to the degeneration of the dopaminergic system. Because of this, 
the possible therapeutic effects of dopamine agonists are being studied in the treatment of 
depression in PD patients (Lemke, 2008). 
Targeting of Reactive Oxygen Species Involved in Pathogenesis 
Another target being heavily researched is related to the production of reactive oxygen 
species, which are produced as toxic byproducts in the dopaminergic neurons. These 
reactive oxygen species can be formed both inside and outside the mitochondria  (Zhou, 
Huang, & Przedborski, 2008). If they are not degraded and disposed of properly, these 
byproducts can be very dangerous to neurons and other cells because they will begin to 
react spontaneously with important compounds in the cell. If this process is not stopped, 
it will almost inevitably lead to apoptosis. 
 Clinical trials are currently being conducted in order to determine the mechanisms 
by which this oxidative stress can occur and the possible ways it can be limited. One 
promising compound for this task is Coenzyme Q10. Coenzyme Q10 helps to balance 
and enhance mitochondrial electron transport and ultimately ATP synthesis. This may 
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allow the mitochondria to function more competently and reduce the production of 
dangerous reactive oxygen species (Sen & West, 2009). 
Regulating Intracellular Calcium Levels 
 The adverse effects of reactive oxygen species in the brain can also be reduced by 
other means. Molecules such as vitamin E, a natural antioxidant, and selenium have been 
tested for their effectiveness at neutralizing the reactive oxygen species. More 
specifically, L-type Ca2+ channels have been shown to be important in the long-term 
survival of dopaminergic neurons. These channels help to regulate the activity of the 
neurons by keeping the concentrations of calcium at a low level inside the cell. The 
endoplasmic reticulum and mitochondria both play a role in this process as well. ATP is 
used to pump calcium out of the cytosol and into these compartments. 
 Additionally, calcium channel blockers are being used in clinical trials. The 
reason for this is to ameliorate the mitochondrial dysfunction seen in the substantia nigra 
of the Parkinson’s Disease brain. If the mitochondria becomes damaged and is not 
functioning properly, as previously described, the L-type Ca2+ channels may not be 
regulating the levels of intracellular calcium any longer. This would lead to an increase in 
intracellular calcium inside of these neurons. 
 An abnormally high level of intracellular calcium is known to cause apoptosis by 
signaling the release of the electron transport protein Cytochrome C from the 
mitochondria. The presence of this mitochondrial protein, Cytochrome C, in the cytosol 
begins a cascade of protein interactions inside the cell that terminates in apoptosis 
(Andreyev & Fiskum, 1999). Because of this, the need for the functioning of these 
calcium channels may play a significant part in the Parkinson’s Disease pathology. 
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 Much ATP is needed for these processes, and so the level of oxidative 
phosphorylation occurring in these cells is quite high. This is characteristic of the 
dopamine-producing neurons. Thus, along with the generation of reactive oxygen 
species, it is clear that this high level of oxidative stress may shorten the lives of these 
cells. Mitochondrial DNA damage is also an important factor in this aging process, 
because its DNA can easily be damaged by the nearby oxygen species (Simunovic et al., 
2009). 
Targeting N-methyl-D-aspartate Receptor Networks 
 A role for N-methyl-D-aspartate (NMDA) receptors, a type of glutamate receptor, 
has also been implicated. The ion channel that is controlled by the NMDA receptor is 
both neurotransmitter-dependent and voltage-dependent. This type of ion channel 
requires a specific chemical neurotransmitter as well as a specific threshold voltage in 
order to work. Magnesium ions (Mg2+) normally block this ion channel when the 
postsynaptic membrane is at its resting potential. This blockage prevents calcium ions 
(Ca2+) from entering through the channel. These ions, because they are polar, are unable 
to pass through the hydrophobic lipid bilayer membrane of the cell (Carlson, 2011). 
 However, once the membrane of the postsynaptic cell becomes depolarized, as the  
result of a passing action potential travelling down the membrane, the magnesium ion is  
displaced. Glutamate then attaches to its binding site, which was previously blocked by 
magnesium, and the ion channel opens so that calcium ions can enter the dendritic spine 
(Carlson, 2011). 
 There is evidence that NMDA receptors promote the survival of the nigrostriatal 
dopaminergic neurons. Although the exact mechanism for this is not known, it has been 
supported by several experiments. The blocking of these receptors using non-competitive 
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antagonists substantially reduced the survival of dopaminergic neurons in one 
experiment. In further support of this hypothesis, when high levels of K+ were induced in 
these same neurons, the L-type Ca2+ channels were activated (Michel et al., 2007). This 
experiment suggests that the blockading of NMDA receptors via this molecule prevents 
the entry of calcium ions through the receptor pore (Katsuki et al. 2003). 
 These observations, along with the pervious research, led to the conclusion that 
NMDA receptors control the firing of the dopaminergic neurons. These receptors regulate 
both the spontaneous and NMDA-induced firing. The complex integration of these 
neurotransmitter receptors and ion channels illustrates the significance of electrical 
activity on the survival or the nigrostriatal dopaminergic neurons. Not only is this delicate 
balance essential to development but it is also vital to the functioning of the adult brain. 
Thus, changes in the electrical currents inside of the brain of a Parkinson’s disease patient 
may contribute to the cell death of the substantia nigra neurons (Michel et al., 2007). 
 The examination of these molecular networks is difficult in that each of the 
neurotransmitter systems is connected to another. For instance, serotonergic neurons can 
aid in process of L-DOPA induced dyskinesia by causing an imbalance in the 
transmission of dopamine (Navailles & De Deurwaerdere, 2012). Additionally, the 
neurons of the subthalamic nucleus contain glutamate, which also interacts with the 
glutamate receptor NMDA (Shen & Johnson, 2010). 
The Potential of Neurosurgery 
 A common neurosurgical option for patients with Parkinson’s disease is deep 
brain stimulation. In the past, neurosurgical procedures have been performed on the 
subthalamic nucleus, thalamus, or globus pallidus pars interna. Recent developments 
have led to the preferential use of deep brain stimulation of the subthalamic nucleus. The 
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subthalamic nucleus and globus pallidus pars interna have increased neuronal activity in 
Parkinson’s Disease. (Williams et al., 2010). 
 These specific brain regions are believed to be responsible directly for motor 
dysfunction symptoms. It was been shown that monkeys with induced parkinsonism can 
be given improved motor function if lesions are made in these brain regions. Lesions can 
also be made in the brains of Parkinson’s disease patients with positive effects on motor 
function. However, there can be a significant amount of damage occurring as side effects 
as well. Fortunately, deep brain stimulation is capable of producing effects very similar to 
that of a lesion except without the disadvantage of destroying brain tissue (Williams et 
al., 2010).  
Expectations for Further Research 
The complex nature of Parkinson’s disease requires that the conclusion of this research, if 
one is ultimately reached, will be equally complex. Given the multifaceted nature of the 
disease and the various primary causes that have been identified, it is clear that treatment 
options will need to be tailored to the individual case. Many different mechanisms have 
been elucidated as time continues, and each of these opens the door to another possibility 
for a treatment option. The more treatment options that can be made available to patients, 
the more promising the results. 
 Overall, the laboratory and clinical research being conducted has tended towards 
that end, and can be expected to continue. Most importantly, although the goal of this 
research is to find common pathways and disease processes which can be targeted by 
medicine, the ultimate purpose is to heal the individual patient. The multidimensional 
aspects of Parkinson’s disease reflect diversity in the patients it affects, and the most 
successful research will take that characteristic into account. 
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